117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781 292 4200
https://www.verastem.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 73
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Daniel W. Paterson | President, CEO & Director | 697.98k | N/A | 1961 |
Mr. Daniel Calkins | CFO, Head of Investor Relations, Principal Accounting & Financial Officer | 1.42M | N/A | 1988 |
Mr. Richard H. Aldrich M.B.A. | Founder and Consultant | 38.39k | N/A | 1954 |
Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board | N/A | N/A | N/A |
Dr. Piyush B. Gupta Ph.D. | Co-Founder | N/A | N/A | N/A |
Dr. Michelle Dipp M.D., Ph.D. | Co-Founder | N/A | N/A | 1976 |
Mr. Robert Pintar M.B.A. | Senior Vice President of Technical Operations | N/A | N/A | N/A |
Dr. Jonathan Pachter Ph.D. | Chief Scientific Officer | 238.18k | N/A | 1958 |
Mr. Nate Sanburn | Senior Vice President of Corporate Development & External Engagement | N/A | N/A | N/A |
Dr. Hagop Youssoufian M.D., M.Sc., Ph.D. | Head of Medical Strategy | N/A | N/A | 1957 |
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Verastem, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 8.